ClinicalTrials.Veeva

Menu

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Immunovant logo

Immunovant

Status and phase

Enrolling
Phase 2

Conditions

Graves' Disease

Treatments

Drug: IMVT-1402
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT06727604
2024-516020-33-00 (EU Trial (CTIS) Number)
IMVT-1402-2502

Details and patient eligibility

About

This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.

The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine [T3] or free triiodothyronine [FT3]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.

Enrollment

240 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Have documented diagnosis of GD.

  • Have a TSH value < 0.1 mIU/L as assessed by the local laboratory at the Screening Visit.

  • Meet one of the following at the Screening Visit:

    • Have been on ATD for ≥ 3 months in the period immediately preceding the Screening Visit and both of the following:

      • Are on ATD at the Screening Visit with an ATD dose a specified amount of methimazole or equivalent for the 4-week period immediately preceding the Screening Visit.
      • Are anticipated to be on a stable dose of ATD for the 4-week period immediately preceding Randomization.
    • Have been on ATD for ≥ 6 months in the period immediately preceding the Screening Visit and all of the following:

      • Have been treated with ≥ 15 mg/day methimazole or equivalent at any point during the participant's treatment history.
      • Are on ATD at the Screening Visit with an ATD dose a specified amount of methimazole or equivalent for the 4-week period immediately preceding the Screening Visit.
      • Are anticipated to be on a stable dose of ATD for the 4-week period immediately preceding Randomization.

Additional inclusion criteria are defined in the protocol.

Exclusion criteria

  • Have previously been treated with radioactive iodine (RAI) therapy or have undergone total thyroidectomy.
  • Have a T3 (Total T3 or FT3, as available and per standard of care at local laboratory) or FT4 value < lower limit of normal (LLN) as assessed by the local laboratory at the Screening Visit.
  • Have received levothyroxine, desiccated thyroid extract, or T3 at any dose within 6 weeks of the Screening Visit.
  • Have a history of hyperthyroidism not caused by GD (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within 6 months of the Screening Visit.
  • Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the participant at undue risk.
  • Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation.

Additional exclusion criteria are defined in the protocol.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

240 participants in 4 patient groups, including a placebo group

Group 1 Period 1 and 2: IMVT-1402
Experimental group
Treatment:
Drug: IMVT-1402
Drug: IMVT-1402
Group 2 Period 1 and 2: IMVT-1402
Experimental group
Treatment:
Drug: IMVT-1402
Drug: IMVT-1402
Group 2 Period 1: IMVT-1402 and Period 2: Placebo
Experimental group
Treatment:
Drug: IMVT-1402
Drug: IMVT-1402
Group 3 Period 1 and 2: Placebo
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

14

Loading...

Central trial contact

Central Study Contact

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems